Antonius P. Schuh
Gründer bei Global Source Ventures LLC
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Stephen L. Zaniboni | M | 65 |
Arcturus Bioscience, Inc.
 Arcturus Bioscience, Inc. Medical SpecialtiesHealth Technology Arcturus Bioscience, Inc. develops laser capture micro dissection instruments and reagents for the analysis of microscopic tissue samples. The private company is based in Carlsbad, CA. The company was founded by Antonius P. Schuh.
Biotheranostics, Inc.
 Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.
Gensignia, Inc.
Global Source Ventures LLC
 Global Source Ventures LLC Investment ManagersFinance Global Source Ventures LLC (Global Source Ventures) is a venture capital firm founded in 2011 by Antonius Schuh and Stephen Zaniboni. The firm is headquartered in San Diego, California.
Quikbyte Software, Inc.
 Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL. | 19 Jahre |
| Mark Erlander | M | 64 |
Biotheranostics, Inc.
Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | 16 Jahre |
| Brigitte Lindsay | F | - | 12 Jahre | |
| Rodney Markin | M | 67 | 10 Jahre | |
| Andreas Klostermann | M | - |
selectION, Inc.
 selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | - |
| Vicki Kelemen | F | - | 9 Jahre | |
| Mark Wiggins | M | 68 |
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | - |
| Donald Scifres | M | - |
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | - |
| Cam Gallagher | M | 54 |
selectION, Inc.
selectION, Inc. BiotechnologyHealth Technology selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA. | 6 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Henry Ji | M | 59 |
Quikbyte Software, Inc.
Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL.
Sorrento Therapeutics, Inc. /Old/
 Sorrento Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Sorrento Therapeutics, Inc. develops human monoclonal antibodies based on its proprietary technology for research, diagnostic and therapeutic use. The company is headquartered in San Diego, CA. | - |
| Paul Kinnon | M | 61 |
Transgenomic, Inc.
 Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 4 Jahre |
| Brett Frevert | M | 61 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 2 Jahre |
| Richard Vincent | M | 61 |
DioGenix, Inc.
 DioGenix, Inc. Medical SpecialtiesHealth Technology DioGenix, Inc. develops and commercializes novel, non-invasive diagnostic, prognostic and treatment response monitoring tests. Its program is designed to provide neurologists with a comprehensive set of clinical tests to diagnose early-stage MS, segment MS patients into clinical sub-types and predict response to treatment, all using non-invasive blood tests. The company was founded by Cam Gallagher, Douglas W. Bigwood and Larry M. Tiffany in September 2008 and is headquartered in Gaithersburg, MD. | 5 Jahre |
| Craig J. Tuttle | M | 71 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 7 Jahre |
| Hubert Köster | M | - | 4 Jahre | |
| Robert M. Patzig | M | 55 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | - |
| Charlie Rodi | M | - | 6 Jahre | |
| Ronald M. Lindsay | M | 76 | 13 Jahre | |
| Alan Weisberg | M | 78 |
Quikbyte Software, Inc.
Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL. | - |
| Martina Molsbergen | F | 59 |
Sorrento Therapeutics, Inc. /Old/
Sorrento Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Sorrento Therapeutics, Inc. develops human monoclonal antibodies based on its proprietary technology for research, diagnostic and therapeutic use. The company is headquartered in San Diego, CA.
Quikbyte Software, Inc.
Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL. | 2 Jahre |
| Glenn Halpryn | M | 63 |
Quikbyte Software, Inc.
Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL. | 1 Jahre |
| Mark P. Colonnese | M | 68 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 2 Jahre |
| Doit L. Koppler | M | 61 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 7 Jahre |
| S. James Freedman | M | 57 |
Sorrento Therapeutics, Inc. /Old/
Sorrento Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Sorrento Therapeutics, Inc. develops human monoclonal antibodies based on its proprietary technology for research, diagnostic and therapeutic use. The company is headquartered in San Diego, CA. | - |
| Richard Ding | M | 54 |
Biotheranostics, Inc.
Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | - |
| Phillip Frost | M | 87 |
Sorrento Therapeutics, Inc. /Old/
Sorrento Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Sorrento Therapeutics, Inc. develops human monoclonal antibodies based on its proprietary technology for research, diagnostic and therapeutic use. The company is headquartered in San Diego, CA. | - |
| Chad M. Richards | M | 54 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 6 Jahre |
| Andreas Olmes | M | - |
University of Bonn
| 6 Jahre |
| John D. Thompson | M | 75 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 2 Jahre |
| Christopher McGuigan | M | 65 | 1 Jahre | |
| Vlada Melnikova | M | - |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 3 Jahre |
| Andreas Pinkwart | M | 64 |
University of Bonn
| 5 Jahre |
| Michael Allen Luther | M | 67 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | - |
| Carin-Martina Tröltzsch | M | 56 |
University of Bonn
| 7 Jahre |
| Peter Brock | M | - |
University of Bonn
| 7 Jahre |
| Hui Huang | M | 61 |
University of Bonn
| 4 Jahre |
| Wald Christoph | M | - |
University of Bonn
| 7 Jahre |
| Paul Billings | M | 71 | - | |
| Norbert Kloppenburg | M | 68 |
University of Bonn
| 10 Jahre |
| Harry Hixson | M | 84 | 12 Jahre | |
| Noah Silver | M | 65 |
Quikbyte Software, Inc.
Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL. | 1 Jahre |
| Jane Hsaio | M | 77 | 3 Jahre | |
| Gregory T. Sloma | M | 71 |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 6 Jahre |
| Michael J. Terry | M | 69 | 5 Jahre | |
| Lewis J. Shuster | M | 68 |
Quikbyte Software, Inc.
Quikbyte Software, Inc. Financial ConglomeratesFinance The Company is develops and markets Computere Software.The Company was Founded in 1989 and it's Headquartered is in Miami,FL. | 1 Jahre |
| Thomas M. Baer | M | - |
Biotheranostics, Inc.
Biotheranostics, Inc. Medical/Nursing ServicesHealth Services Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA. | - |
| Elizabeth Anderson | F | - | 2 Jahre | |
| Joanne M. Lewis | F | - |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | - |
| Walter Schäfers | M | 69 |
University of Bonn
| 6 Jahre |
| Simon Dorling | M | 61 |
University of Bonn
| 1 Jahre |
| Johannes Geismann | M | 64 |
University of Bonn
| 5 Jahre |
| Dae-Woo Kwon | M | 64 |
University of Bonn
| 8 Jahre |
| Thomas Laubach | M | - |
University of Bonn
| 4 Jahre |
| Barbara Ooms-Gnauck | M | 66 |
University of Bonn
| 4 Jahre |
| Sudipto Sur | M | - | 3 Jahre | |
| Daniel von Borries | M | 59 |
University of Bonn
| 4 Jahre |
| Wolfgang Hiller | M | 63 |
University of Bonn
| 1 Jahre |
| Amin Shokrollahi | M | - |
University of Bonn
| 3 Jahre |
| Harald D. Zenke | M | 64 |
University of Bonn
| 4 Jahre |
| Nick Nelson | M | 41 | 3 Jahre | |
| Klaus Gottlieb | M | - |
University of Bonn
| 3 Jahre |
| Lutz Goedde | M | - |
University of Bonn
| 9 Jahre |
| Rolf Vornhagen | M | 71 |
University of Bonn
| 3 Jahre |
| Andreas Kuhlmann | M | - |
University of Bonn
| 3 Jahre |
| Karsten Schmidt | M | 62 | 2 Jahre | |
| Tim Fiedler | M | 57 |
University of Bonn
| 5 Jahre |
| Martin Wiesmann | M | 59 |
University of Bonn
| 7 Jahre |
| Andreas Mündel | M | - |
University of Bonn
| 9 Jahre |
| Tristan B. Orpin | M | 58 | 3 Jahre | |
| Matthew Posard | M | 56 | 1 Jahre | |
| Hans-Peter Burghof | M | 60 |
University of Bonn
| 5 Jahre |
| Wolf Frederic Kupatt | M | 63 |
University of Bonn
| 4 Jahre |
| Michael Klein | M | - |
University of Bonn
| 8 Jahre |
| Beda Bolzenius | M | 68 |
University of Bonn
| 3 Jahre |
| Robert Kelley | M | 52 | 2 Jahre | |
| Joachim Coers | M | 59 |
University of Bonn
| 4 Jahre |
| Hans-Joachim Strüder | M | 69 |
University of Bonn
| 7 Jahre |
| Christoph Dänzer-Vanotti | M | 69 |
University of Bonn
| 4 Jahre |
| Christian Diedrich | M | 67 |
University of Bonn
| 4 Jahre |
| Andreas Gebhard Rittstieg | M | 68 |
University of Bonn
| 3 Jahre |
| Marina Attawar | F | 66 |
University of Bonn
| 4 Jahre |
| Martin Wienke | M | 59 |
University of Bonn
| 6 Jahre |
| Karl-Michael Fuhr | M | 66 |
University of Bonn
| 1 Jahre |
| Jörg Hager | M | - |
University of Bonn
| 3 Jahre |
| Thomas Enders | M | 64 |
University of Bonn
| 5 Jahre |
| Detlev Schwabe | M | - |
University of Bonn
| 4 Jahre |
| Guang Guo | M | 66 |
University of Bonn
| 3 Jahre |
| Simone Bagel-Trah | M | 55 |
University of Bonn
| 5 Jahre |
| Hans J. Walitzki | M | - |
University of Bonn
| 3 Jahre |
| Fritz Oidtmann | M | 64 |
University of Bonn
| 6 Jahre |
| Frank Losem | M | - |
University of Bonn
| 4 Jahre |
| David Moskowitz | M | - | - | |
| Zbigniew Roger Mrowiec | M | - |
University of Bonn
| 3 Jahre |
| Jay Lichter | M | 62 | - | |
| Olov Arvid Sterner | M | 71 |
University of Bonn
| 3 Jahre |
| Claus Recktenwald | M | 65 |
University of Bonn
| 3 Jahre |
| Thomas Hawel | M | 61 |
University of Bonn
| 4 Jahre |
| Helmut Schühsler | M | 65 | 7 Jahre | |
| John P. Sharp | M | 59 | 3 Jahre | |
| Goetz Kalckreuth | M | - |
University of Bonn
| 5 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 51 | 51,00% |
| Deutschland | 49 | 49,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Antonius P. Schuh
- Persönliches Netzwerk
